{"podcast":{"title":"BioSpace","slug":"biospace-6696251","podcast_index_feed_id":6696251,"rss_url":"https://api.riverside.fm/hosting/3SxyDAXU.rss","website_url":"https://www.biospace.com/","image_url":"https://hosting-media.riverside.com/media/imports/podcasts/a2a52916-bfe1-4f2a-b9a3-9be5029ecbe4/39510587-1699400129885-1e919ae7cb2aa.jpg","author":"BioSpace","episode_count":247,"summary":"Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.","last_synced_at":"2026-07-15T16:19:04.105662+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251"},"episode":{"title":"Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup","slug":"biogen-validates-anti-tau-approach-at-aaic-psychedelics-full-speed-ahead-attr-cm-shakeup","published_at":"2026-07-15T07:00:00+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251/biogen-validates-anti-tau-approach-at-aaic-psychedelics-full-speed-ahead-attr-cm-shakeup","show_page_url":"https://stenobird.com/podcast/biospace-6696251","url":"https://api.riverside.com/hosting-analytics/media/874db7e54d926518b357f18c70ab304281df29be048bb454375512d425cda6ef/eyJlcGlzb2RlSWQiOiI3Y2U0YWM1Yi1hYzQyLTRjYzYtODY4Mi1kYTFhNDI3OWRhZWYiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE1Njg1OGYyY2UxMTM1ZGUxMDQ2YmI4L2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi03LTE0X18yMC01My0zLm1wMyJ9.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/874db7e54d926518b357f18c70ab304281df29be048bb454375512d425cda6ef/eyJlcGlzb2RlSWQiOiI3Y2U0YWM1Yi1hYzQyLTRjYzYtODY4Mi1kYTFhNDI3OWRhZWYiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE1Njg1OGYyY2UxMTM1ZGUxMDQ2YmI4L2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi03LTE0X18yMC01My0zLm1wMyJ9.mp3","summary":"Biogen’s new data, presented at the Alzheimer's Association International Conference, supports a tau-focused approach to the intractable neurodegenerative disease; psychedelics are back in the news with more positive data from Compass Pathways and final guidance from the FDA; and the ATTR-CM space got a major shakeup with the late-stage failure of AstraZeneca and Ionis’ antisense therapeutic.","meta_description":"Biogen’s new data, presented at the Alzheimer's Association International Conference, supports a tau-focused approach to the intractable neurodegenerative…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1282,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/biogen-validates-anti-tau-approach-at-aaic-psychedelics-full-speed-ahead-attr-cm-shakeup/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biospace-6696251/biogen-validates-anti-tau-approach-at-aaic-psychedelics-full-speed-ahead-attr-cm-shakeup.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}